Showing 2773 results
-
Biography /
-
Press release /Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring…
-
Press release /Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as…
-
Press release /Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic…